These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 8499332

  • 1. 5 alpha-Dihydro-11-deoxycorticosterone as a mineralocorticoid agonist and antagonist: evidence for a weak mineralocorticoid as an antagonist of potent mineralocorticoids.
    Sekihara H, Yazaki Y.
    J Steroid Biochem Mol Biol; 1993 Apr; 45(4):235-8. PubMed ID: 8499332
    [Abstract] [Full Text] [Related]

  • 2. New mineralocorticoids: 5alpha-dihydroaldosterone and 5alpha-dihydro-11-deoxycorticosterone.
    Sekihara H, Island DP, Liddle GW.
    Endocrinology; 1978 Oct; 103(4):1450-2. PubMed ID: 744157
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the mineralocorticoid activity of 19-oxygenated and 19-nor derivatives of deoxycorticosterone.
    Melby JC, Griffing GT, Holbrook M, Wilson TE, Johnston JO.
    Steroids; 1991 Nov; 56(11):552-7. PubMed ID: 1814021
    [Abstract] [Full Text] [Related]

  • 4. Further studies of the mineralocorticoid activity of 19-oxo-deoxycorticosterone.
    Kenyon CJ, Saccoccio NA, Morris DJ.
    Endocrinology; 1984 Aug; 115(2):535-7. PubMed ID: 6745168
    [Abstract] [Full Text] [Related]

  • 5. 19-Nor deoxycorticosterone (19-nor DOC): mineralocorticoid receptor affinity higher than aldosterone, electrolyte activity lower.
    Funder JW, Mercer J, Ingram B, Feldman D, Wynne K, Adam WR.
    Endocrinology; 1978 Oct; 103(4):1514-7. PubMed ID: 744165
    [Abstract] [Full Text] [Related]

  • 6. Progestogens with antimineralocorticoid activity.
    Losert W, Casals-Stenzel J, Buse M.
    Arzneimittelforschung; 1985 Oct; 35(2):459-71. PubMed ID: 4039568
    [Abstract] [Full Text] [Related]

  • 7. Mineralocorticoid activity of 19-nor-DOC and 19-OH-DOC in adrenalectomized rat.
    Perrone RD, Bengele HH, Dale SL, Melby JC, Alexander EA.
    Am J Physiol; 1982 May; 242(5):E305-8. PubMed ID: 7081431
    [Abstract] [Full Text] [Related]

  • 8. The "mineralocorticoid-like" actions conferred on corticosterone by carbenoxolone are inhibited by the mineralocorticoid receptor (type I) antagonist RU28318.
    Souness GW, Morris DJ.
    Endocrinology; 1991 Nov; 129(5):2451-6. PubMed ID: 1657575
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, Ishikawa H, Mizuno M, Sada T.
    Eur J Pharmacol; 2015 Aug 15; 761():226-34. PubMed ID: 26073023
    [Abstract] [Full Text] [Related]

  • 10. Are we missing a mineralocorticoid in teleost fish? Effects of cortisol, deoxycorticosterone and aldosterone on osmoregulation, gill Na+,K+ -ATPase activity and isoform mRNA levels in Atlantic salmon.
    McCormick SD, Regish A, O'Dea MF, Shrimpton JM.
    Gen Comp Endocrinol; 2008 May 15; 157(1):35-40. PubMed ID: 18462736
    [Abstract] [Full Text] [Related]

  • 11. The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.
    Bamberg K, William-Olsson L, Johansson U, Jansson-Löfmark R, Hartleib-Geschwindner J.
    J Renin Angiotensin Aldosterone Syst; 2019 May 15; 20(1):1470320319827449. PubMed ID: 30813831
    [Abstract] [Full Text] [Related]

  • 12. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
    Eudy RJ, Sahasrabudhe V, Sweeney K, Tugnait M, King-Ahmad A, Near K, Loria P, Banker ME, Piotrowski DW, Boustany-Kari CM.
    J Transl Med; 2011 Oct 21; 9():180. PubMed ID: 22017794
    [Abstract] [Full Text] [Related]

  • 13. Mineralo- and glucocorticoid effects on renal excretion of electrolytes.
    Campen TJ, Vaughn DA, Fanestil DD.
    Pflugers Arch; 1983 Oct 21; 399(2):93-101. PubMed ID: 6647008
    [Abstract] [Full Text] [Related]

  • 14. Azolimine: a nonsteroidal antagonist of the effects of mineralocorticoids on renal electrolyte excretion.
    Gussin RZ, Ronsberg MA, Stokey EH, Cummings JR.
    J Pharmacol Exp Ther; 1975 Oct 21; 195(1):8-15. PubMed ID: 1181406
    [Abstract] [Full Text] [Related]

  • 15. Ouabain causes kaliuresis and works synergistically with aldosterone in vivo.
    Sekihara H, Yazaki Y.
    Life Sci; 1993 Oct 21; 53(12):975-80. PubMed ID: 8361328
    [Abstract] [Full Text] [Related]

  • 16. Effects of mineralocorticoids on Na+ and K+ excretion in the adrenalectomized rat.
    Horisberger JD, Diezi J.
    Am J Physiol; 1983 Jul 21; 245(1):F89-99. PubMed ID: 6869541
    [Abstract] [Full Text] [Related]

  • 17. 5 alpha-Dihydro-11-deoxycorticosterone: effect on blood pressure in the rat.
    Carroll J, Komanicky P, Melby JC.
    Steroids; 1981 Jan 21; 37(1):111-20. PubMed ID: 7222141
    [Abstract] [Full Text] [Related]

  • 18. Effect of 6-dehydro-DOCA and 6-dehydro-9 alpha-fluorocortisol acetate on the excretion of sodium and potassium in the rat.
    Genard P, Palem-Vliers M.
    J Steroid Biochem; 1985 Nov 21; 23(5A):673-5. PubMed ID: 4079383
    [Abstract] [Full Text] [Related]

  • 19. 19-Hydroxyandrostenedione amplifies the hypertensive action of mineralocorticoids in rats.
    Sekihara H, Yazaki Y, Kojima T.
    J Endocrinol; 1993 Jul 21; 138(1):31-40. PubMed ID: 7852890
    [Abstract] [Full Text] [Related]

  • 20. 18-oxocortisol, a naturally occurring mineralocorticoid agonist.
    Ulick S, Land M, Chu MD.
    Endocrinology; 1983 Dec 21; 113(6):2320-2. PubMed ID: 6641637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.